Trials: Early Drug Studies

You are here:

Find a Clinical Trial
Early Drug Studies

NCT04657068 – A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

June 20, 2024

NCT04794699 – An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) in Adult Participants with Advanced Solid Tumors

July 24, 2024

NCT05023486 – NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

June 20, 2024

NCT05252416 – A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

July 24, 2024

NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

June 20, 2024

NCT05675449 – A Phase 1b, Open-Label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma

June 20, 2024

NCT05815160 – A Phase 1, Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination with Carboplatin and Etoposide in Adult Participants with Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

June 20, 2024